NSTEMI

ESO Releases 2023 ESO EMS Index to Explore Key Trends and Measures Affecting EMS Agencies across the Country

Retrieved on: 
Tuesday, April 11, 2023
Technology, Hospitals, Health Technology, Cardiology, Software, Other Health, General Health, Pharmaceutical, Health, Data Management, Naloxone, ESO, EKG, Respiratory rate, Stroke, NSTEMI, Record, STEMI, Research, Attention, EMS, JPMorgan GBI-EM Index, Capnography, Hospital, Oxygen saturation (medicine), Patient, Emergency medical services, Ketamine, Drug, Periodic breathing, CPR, Public health surveillance, Nursing, Medical device

ESO, the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2023 ESO EMS Index .

Key Points: 
  • ESO, the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2023 ESO EMS Index .
  • Additionally, this year’s Index takes a deeper look at patient race/ethnicity and gender across metrics to identify inequities in care.
  • “Ketamine use in EMS has been a topic of interest in recent years due to patient safety concerns.
  • Additionally, as the Index findings indicates, there is opportunity for improvement in monitoring a patient’s EtCO2 following administration of ketamine.”
    The full 2023 ESO EMS Index can be downloaded here.

Study Finds Patients Without Standard Modifiable Heart Risk Factors Are Common and More Likely to Fare Better After Heart Attack Than Patients with Known Factors

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Hospital, Health, Artery, Cardiovascular disease, Risk, Diabetes, Smoking, American Heart, C-reactive protein, Research, Hope, MD, Intermountain Healthcare, Inflammation, Patient, Physician, Heart, NSTEMI, Infarction, Myocardial infarction, Lake City, Oxygen, Medical device, Pharmaceutical industry, Medical imaging, Intermountain

For heart attacks that come from blocked arteries (ST-elevation heart attacks) its one in four patients.

Key Points: 
  • For heart attacks that come from blocked arteries (ST-elevation heart attacks) its one in four patients.
  • In heart attacks where oxygen is still getting to the heart but not enough (non-ST-elevation heart attacks, which are more common), its one in five patients.
  • In the new study, Intermountain researchers examined non-ST-elevation heart attack patients and found that those without known modifiable risk factors fared better than those with them.
  • They found that these patients were slightly less likely to have revascularization procedures than heart attack patients with known modifiable risk factors.

CathWorks Announces Key Events for TCT 2022

Retrieved on: 
Thursday, September 15, 2022
Rabin Medical Center, Faculty, Expert, Trial of the century, Twitter, Columbia University, LinkedIn, NSTEMI, Senior, FFR, Partnership, Treatment, Coronary artery disease, Patient, Physiology, Boston Convention and Exhibition Center, Intelligence, Physician, CEO, Standard of care, Columbia University Irving Medical Center, CA, Medtronic, Cardiovascular disease, CAD, Convention center, PCI, Stanford University Medical Center, Comparison, Coronary, TCT, Pharmaceutical industry, Nightclub, Medical device, Diagnosis

KFAR-SABA, Israel & IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- CathWorks announced today the schedule of key events for the company during Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference taking place September 16 to 19 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

Key Points: 
  • KFAR-SABA, Israel & IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- CathWorks announced today the schedule of key events for the company during Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) 2022 conference taking place September 16 to 19 at the Boston Convention and Exhibition Center in Boston, Massachusetts.
  • CathWorks, in partnership with Medtronic and as part of the recently announced strategic partnership between the two companies, is pleased to sponsor multiple educational events at TCT.
  • Attendees can register for CathWorks events at TCT 2022 through the following link: https://ww2.cath.works/tct2022
    CathWorks is the leader in digital health innovations that can improve the lives of patients globally.
  • For more information on CathWorks, visit www.cath.works and follow @CathWorks on Twitter and LinkedIn .

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

Retrieved on: 
Friday, August 26, 2022
Harvard Medical School, Cardiovascular disease, CVD, European Society of Cardiology, Hospital, STEMI, CV, Hypertriglyceridemia, NASDAQ, IPE, MI, Risk, Myocardial infarction, NSTEMI, Professional corporation, GLOBE, ESC, Adult, Diabetes, Congress, Patient, Pharmaceutical industry, Medicine, Brigham

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) significantly reduced ST-segment elevation myocardial infarction (STEMI), non-ST segment elevated myocardial infarction (NSTEMI), and other MI subtypes in patients with established cardiovascular disease (CVD) or diabetes with risk factors.

Key Points: 
  • The REDUCE-IT data presented today show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo.
  • Importantly, these new data show a significant reduction in the most important type of heart attack known as STEMI, as well as other MI subtypes.
  • Prespecified and post hoc analyses examined MI subtypes, which were independently adjudicated by a blinded Clinical Endpoint Committee.
  • IPE significantly reduced STEMI (HR=0.60; 95% CI 0.44, 0.81; P=0.0008) and NSTEMI (HR=0.73; 95% CI 0.60, 0.89; P=0.001).

Treatment for Heart Attacks Improving but Gaps in Access Persist, New Study Shows

Retrieved on: 
Wednesday, June 22, 2022
Doctor of Philosophy, Time, ACEP, American College of Emergency Physicians, STEMI, Vein, Artery, Mortality, Angiography, Female, Emergency medicine, Insurance, American College, Man, Blood, Research, Gaps, Attending physician, University, NSTEMI, Annals of Emergency Medicine, Record, Education, Color, Patient, Multimedia, Geography, Male, Woman, Pharmaceutical industry, Medicine, MD

Timely access to angiography is defined for this study as treatment on the day of hospital admission for STEMI patients and within three days of admission for NSTEMI patients.

Key Points: 
  • Timely access to angiography is defined for this study as treatment on the day of hospital admission for STEMI patients and within three days of admission for NSTEMI patients.
  • The proportion of patients who received timely treatment increased and mortality decreased over time for men and women.
  • However, while gaps in treatment and outcomes between genders narrowed over time, these disparities persisted over the course of the years analyzed.
  • "But there are biases and social issues that challenge access to care and impact the treatment of women and patients of color with heart issues.

Chiesi USA Announces First Analysis from the CAMEO Registry Assessing KENGREAL® (cangrelor) Use and Transition to Oral P2Y12 Inhibitors in Routine Clinical Practice

Retrieved on: 
Wednesday, June 1, 2022
Cardiac catheterization, Percutaneous coronary intervention, Company, STEMI, Gaps, Benefit corporation, Effectiveness, Duke University Hospital, CARE, Research, Cardiology, Journal of the American Heart Association, Community, Cangrelor, Journal, MBA, Partnership, Bleeding, American College, NSTEMI, CABG, Respiration, Development, Health, MD, Carbon, PCI, B Corporation (certification), Clopidogrel, MHS, National Healthcare Group, Hypersensitivity, MI, Anaphylaxis, Patient, Hospital, Juan S.P. Hidalgo Jr., Injection, AIR, Education, Cystic fibrosis, Adult, Neonatology, Environment, GLOBE, Risk, CAMEO, Myocardial infarction, RARE, American Heart Association, Pharmaceutical industry, Medical imaging, Birth control, Group, Chiesi Farmaceutici, Chiesi Farmaceutici

CARY, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced its first full analysis publication from the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry that evaluated KENGREAL (cangrelor) use and transition to oral P2Y12 inhibitors in routine clinical practice.

Key Points: 
  • CARY, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced its first full analysis publication from the CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry that evaluated KENGREAL (cangrelor) use and transition to oral P2Y12 inhibitors in routine clinical practice.
  • The registry aims to collect information on 3,000 patients with NSTEMI or STEMI treated with KENGREAL or an oral P2Y12 inhibitor among 12 sites.
  • Sites were selected to represent a wide geographic distribution and variety of types of U.S. university- and non-university based hospitals.
  • The analysis was able to characterize KENGREAL dosing and patterns of transition to an oral P2Y12 inhibitor in routine practice.

ESO Launches 2022 ESO EMS Index to Track Nationwide Emergency Medical Services Performance Across Key Metrics

Retrieved on: 
Monday, March 21, 2022
Public Policy, Government, Software, Health, Law Enforcement, Emergency Services, Data Management, Hospitals, Technology, Other Technology, Risk, Population, EMS, JPMorgan GBI-EM Index, Gaps, Research, HDE, Hospital, Ketamine, Health, Drug, Resuscitation, Solution, Burn, Documentation, Industry, Safety, Acquisition, Emergency medical services, Stroke, EHR, EKG, Capnography, NSTEMI, Data, Attention, Trauma, COVID, STEMI, ESO, Patient, Gq alpha subunit, Medical device, Pharmaceutical industry, Cryptocurrency, THE INDEX, ESO, THE INDEX, ESO

ESO , the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2022 ESO EMS Index .

Key Points: 
  • ESO , the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2022 ESO EMS Index .
  • Stroke Assessment Performance: The data show a slightincrease in the number ofstroke assessments performedat 73 percent, up from 72 percent in 2020.
  • 12-lead EKG with ED-diagnosed STEMI/NSTEMI: Approximately 70 percent of EMS patients who were diagnosed with a STEMI or NSTEMI in the emergency department had a documented 12-lead EKG.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

MemorialCare Heart & Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II)

Retrieved on: 
Thursday, March 3, 2022
Risk, Dialysis, WHO, Apolipoprotein A1, ACS, Patient, Adult, Hospital, Research, Infarction, World, Korea Disease Control and Prevention Agency, HDL, Physician, Apolipoprotein, Safety, Percutaneous coronary intervention, D.O, STEMI, Multimedia, Cholesterol, NSTEMI, Stroke, PCI, Artery, CDC, Cardiology, CSL, Center, Health, CSL Behring, Long Beach Medical Center, Medical Center, World Health Organization, MACE, Acute coronary syndrome, Pharmaceutical industry

All three adult hospitals within MemorialCare's health system MemorialCare Long Beach Medical Center , MemorialCare Orange Coast Medical Center in Fountain Valley, and MemorialCare Saddleback Medical Center in Laguna Hills are providing access to this study to their cardiac patients.

Key Points: 
  • All three adult hospitals within MemorialCare's health system MemorialCare Long Beach Medical Center , MemorialCare Orange Coast Medical Center in Fountain Valley, and MemorialCare Saddleback Medical Center in Laguna Hills are providing access to this study to their cardiac patients.
  • Of these, 600,000 are a first heart attack and 200,000 happen to people who have already suffered a heart attack, according to the Centers for Disease Control and Prevention (CDC).
  • As a result, an increasing number of patients are being treated for cardiovascular conditions, such as stroke and heart attack.
  • "The MemorialCare Heart & Vascular Institute is proud to continue MemorialCare's tireless efforts to remain at the forefront of innovative clinical research studies," says David Shavelle, M.D.